Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Webcasts|September 27, 2019
APIs and ADCs: a journey through high potency
Author(s)Lonza Pharma & Biotech
Drug development based on potent compounds can be quite challenging. Crossing the boundary from small molecule to biologics into antibody-drug conjugate (ADC) territory adds levels of complexity. Learn more about infrastructure requirements and best practices. Live: Friday, Sept. 27, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Sept. 27, 2020 Register free
Register free:
Event Overview:
Drug development based on potent compounds can be quite challenging. Crossing the boundary from small molecule to biologics into antibody-drug conjugate (ADC) territory adds levels of complexity.
In this webcast, experts will elaborate on best practices and infrastructure requirements that facilitate accelerated timelines to clinic.
Topics include:
- The advantages of seamless integration of highly potent APIs, monoclonal antibodies, and ADC operations
- The impact of supporting integrated service offerings on expansion strategies
- ADC process scale-up from clinical manufacturing to commercial drug substance production
- A case study will review the development, rapid scaling, and commercial production of HPAPI drug substance
Speakers: Maurits Janssen, PhD, Senior Director Head of Commercial Development, API, Lonza Pharma & Biotech
Bernhard Stump, PhD, Head of Process Development Bioconjugates, Lonza Pharma & Biotech
Time and date: Friday, Sept. 27, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Sept. 27, 2020
Sponsor: Lonza Pharma & Biotech
Register free:
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5